LTR PharmaASX:LTP -4.27%15 Pretax Margin % is -7,785.14% as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, LTR Pharma ranks worse than 90.7% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. LTR Pharma's Pre-Tax Income for the
six
months ended in Dec. 2025 was A$-5.76 Mil. LTR Pharma's Revenue for the
six
months ended in Dec. 2025 was A$0.07 Mil. Therefore, LTR Pharma's pretax margin for the quarter that ended in Dec. 2025 was -7,785.14%.
The historical rank and industry rank for LTR Pharma's Pretax Margin % or its related term are showing as below:
ASX:LTP'
s Pretax Margin % Range Over the Past 10 Years
Min: -5700.64 Med: -3831.51 Max: -3831.51
Current: -5700.64
ASX:LTP's Pretax Margin % is ranked worse than 90.7% of 946
companies
in the Biotechnology industry
Industry Median: -90.5
vs ASX:LTP: -5700.64
LTR Pharma (ASX:LTP) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
LTR Pharma Pretax Margin % Related Terms
LTR Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for LTR Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LTP vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, LTR Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where LTR Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTR Pharma (ASX:LTP) has a Pretax Margin % of -7,785.14% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on LTR Pharma and its competitors. According to the industry distribution chart, LTR Pharma ranks #858 out of 946 companies in the Biotechnology industry, placing it in the top 90.7%.
Is LTR Pharma's Pretax Margin % too high?
LTR Pharma's current Pretax Margin % is -7,785.14%. Based on the distribution chart, LTR Pharma ranks #858 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #858 out of 946 companies for Pretax Margin %. This places LTR Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on LTR Pharma and its competitors. LTR Pharma's current Pretax Margin % is -7,785.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Pretax Margin % of -7,785.14%. The current Pretax Margin % is -7,785.14%. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Pretax Margin % is -7,785.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score
Get the complete analysis for ASX:LTP
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 